Abstract
Regulation of intracellular cyclic nucleotides to avoid homeostatic imbalances is achieved through catabolic activity of phosphodiesterases (PDEs). Recently, Ajiboye et al. reported validation of Cryptosporidium PDE1 (CpPDE1) as a viable drug target and identified optimized pyrazolopyrimidines with selective activity against CpPDE1 over human PDEs and with potent anticryptosporidial efficacy.
Original language | English (US) |
---|---|
Pages (from-to) | 1075-1076 |
Number of pages | 2 |
Journal | Trends in Parasitology |
Volume | 40 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2024 |
Keywords
- Cryptosporidium
- cyclic-nucleotides
- drug-target
- phosphodiesterases
- pyrazolopyrimidines
- selective-inhibition
ASJC Scopus subject areas
- Parasitology
- Infectious Diseases